Introduction
Methods
Six-Minute Walk Test
Statistical Analysis
Results
n = 49 | Time since diagnosis <1 year n = 14 | Time since diagnosis >1 year n = 35 | |
---|---|---|---|
Gender, male, n (%) | 26 (53) | 5 (36) | 21 (60) |
Age, years | 11.9 (7.4–15.1) | 12.1 (8.6–16.0) | 11.8 (8.3–14.1) |
Time since DCM diagnosis, years | 3.6 (0.6–7.4) | 0.1 (0.1–0.5) | 6.2 (3.1–9.2) |
Cause of DCM, n (%) | |||
Idiopathic | 24 (49) | 6 (43) | 18 (51) |
Myocarditis | 7 (14) | 0 (0) | 7 (20) |
Other | 18 (37) | 8 (57) | 10 (29) |
Medication used, n (%) | |||
Beta-blocker | 38 (78) | 9 (64) | 29 (91) |
ACE-inhibitor | 46 (94) | 14 (100) | 32 (91) |
Spironolactone | 27 (55) | 8 (57) | 19 (54) |
Loop diuretics | 25 (51) | 8 (57) | 17 (49) |
Digoxin | 8 (16) | 1 (7) | 7 (20) |
NT-proBNP (pmol/L) | 221 (51–555) | 451 (248–735) | 102 (32–472) |
LVEDD z-score | 5.0 ± 3.2 | 4.7 ± 2.1 | 5.2 ± 3.5 |
Fractional shortening, % | 18 ± 6 | 15 ± 7 | 19 ± 6 |
LV ejection fraction, % | 33 ± 12 | 25 ± 11 | 36 ± 12 |
Endpoint, n (%) | 10 (20) | ||
Death | 0 | ||
Heart transplantation | 10 (100) | 3 | 7 |
Follow-up since 6MWT, months | 33 (14–50) | 24 (12–31) | 45 (14–53) |
6MWD, m | 448 ± 144 | 401 ± 88 | 466 ± 88 |
6MWD%, % | 70 ± 21 | 62 ± 15 | 73 ± 22 |
Six-Minute Walk Test Results
Age range (years) |
n*
| SaO2
|
n* | Heart rate (bpm) | % of max | ||
---|---|---|---|---|---|---|---|
Pre-6MWT | Post-6MWT | Pre-6MWT | Post-6MWT | Post-6MWT | |||
6–8 | 9 | 99 (98, 100) | 98 (95, 98) | 11 | 94 ± 13 | 132 ± 16 | 66 ± 8 |
8–12 | 10 | 99 (98, 100) | 98 (97, 98) | 11 | 88 ± 13 | 125 ± 20 | 63 ± 10 |
12–15 | 12 | 98 (98, 99) | 97 (97, 98) | 12 | 85 ± 15 | 121 ± 16 | 61 ± 8 |
15–18 | 10 | 98 (97, 99) | 97 (96, 98) | 10 | 85 ± 19 | 117 ± 18 | 58 ± 9 |
Outcome
Potential risk factors for outcome | Primary endpoint (n = 10) | No primary endpoint (n = 39) | Hazard ratio (95% CI) |
p value |
---|---|---|---|---|
6MWD%, % | 55 ± 23 | 74 ± 19 | 0.95 (0.91–0.99) | 0.006 |
6MWD% < 63%, n (%) | 8 (80) | 12 (31) | 7.51 (1.59–35.5) | 0.011 |
Age at DCM diagnosis ≥ 6 years, n (%) | 6 (60) | 18 (46) | 2.02 (0.57–7.24) | 0.27 |
NT-proBNP (pmol/L) | 569 (364–742) | 99 (32–420) | 30.1 (1.9–479)a
| 0.016 |
LVEDD z-score | 7.0 ± 4.2 | 4.5 ± 2.7 | 1.25 (1.02–1.53) | 0.032 |
Fractional shortening, % | 14 ± 5 | 19 ± 6 | 0.86 (0.75–0.97) | 0.016 |
LV ejection fraction, % | 21 ± 8 | 36 ± 11 | 0.88 (0.81–0.96) | 0.003 |